Eigen RadarEconomics
Archive
Analysis

CSL commits 355 million dollars and development funding to Alentis deal

CSL and Alentis Therapeutics agreed to develop and promote the investigational kidney and liver treatment lixudebart. CSL commits an initial 355 million dollars, funds development, and could pay up to 1.2 billion dollars more at commercial milestones. The partners have also arranged a future profit split. The agreement funds clinical work while the treatment remains investigational.

Economics & Markets··Midday
Blue-gloved hands work with a pipette and a small glass vial in a laboratory.

The partnership starts with 355 million dollars

Australian biopharmaceutical company CSL agreed with Swiss developer Alentis Therapeutics to jointly develop and promote lixudebart, an investigational treatment for rare kidney and liver diseases. The agreement brings an initial payment of 355 million dollars from CSL to Alentis.[1], [2]

Alentis is eligible for up to another 1.2 billion dollars at commercial milestones. Those payments depend on specified commercial stages. CSL’s development spending is arranged separately from the upfront and milestone payments. The company has not disclosed a total budget for the future development programme.[1]

CSL funds the kidney and liver trials

CSL is fully funding completion of the ongoing Phase 2 RENAL trial and a planned Phase 3 trial for a rare autoimmune kidney disease. It also funds Phase 2 work in another chronic kidney disease and a chronic liver disease, together with supporting development activities.[1]

Future profits have a defined split

Once the treatment is commercialised, the agreement allocates 55 per cent of global profits to CSL and 45 per cent to Alentis. The treatment remains investigational. CSL research chief Bill Mezzanotte linked the collaboration to expansion of the company’s kidney-disease business through external partnerships.[1]

For more information on this topic, you can read the related columns.

References

  1. News sourceCSLCSL commits 355 million dollars upfront to Alentis partnership↩1↩2↩3↩4
  2. News sourceRask MediaCSL commits 355 million dollars and development funding to Alentis deal↩
Chip wars and the supply chainRussia-Ukraine warCentral banks and the rate cycleEnergy transition and climate

More analysis from this desk

View all Brief analyses from the Economics & Markets desk →